Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix Inc. (NASDAQ: AFFX) today announced the full commercial
launch of the GeneChip®
Human Gene 1.0 ST Array, the latest addition to its whole-transcript
assay-based gene expression product family. The new microarray measures
the overall expression of all transcripts derived from a gene, not just
the 3’ end of a gene. As a result, the Human
Gene 1.0 ST Array delivers a more complete and accurate view of a gene’s
total transcription activity compared to traditional expression array
designs.
The Human Gene 1.0 ST Array is a cost-effective gene expression
profiling option for new microarray users. Its affordable price and
simplified workflow will enable more scientists to incorporate
microarray technology in their research more often. Researchers will
also be able to perform larger expression studies with additional
replicates to gain a more accurate picture of gene activity. The latest
Affymetrix product complements the more comprehensive Human Exon 1.0 ST
Array, which offers both gene-level expression profiling and alternative
splicing analysis in a single experiment.
“The new Human Gene 1.0 ST Array offers the
latest available content at an attractive price point, making it an
ideal solution for researchers with restricted budgets who were not able
to work with Affymetrix technology in the past,”
said Shawn Levy, Ph.D., assistant professor of biomedical informatics
and director of the Vanderbilt Microarray Shared Resource. “With
the gene and exon arrays on the same WT assay platform, Affymetrix
provides a logical product progression that enables customers to gain an
understanding of the critical roles that gene expression or alternative
splicing play in biology.“
In the Human Gene 1.0 ST Array design, each of the 28,869 genes is
represented by a set of approximately 26 probes. This simplified design
strategy provides one value from one probe set for each gene, yielding a
more accurate representation of all of the transcription activities for
each gene of interest than traditional expression array designs.
Affymetrix Expression Console™ Software offers
additional tools to further simplify the analysis workflow, making it as
easy to interpret gene-level expression on Human Gene 1.0 ST Arrays as 3’-based
expression microarrays.
“Between the traditional 3’
U133 Array, the new-generation Human Exon 1.0 ST Array and now the Human
Gene 1.0 ST Array, Affymetrix has the most complete portfolio of gene
expression products to meet the growing and diverging customer demands,”
said Sean George, vice president of the academic business unit at
Affymetrix. “The new Human Gene 1.0 ST Array
complements the Human Exon 1.0 ST Array, offering an additional choice
for new microarray users on the gold-standard microarray platform at a
very affordable price. This product is a direct result of Affymetrix’
continued innovation and dedication to making larger-scale genomic
studies more economical.”
The Affymetrix Human Gene 1.0 ST Array utilizes the same GeneChip
technology that has been the industry standard in microarray research
for the past decade. More than 1,500 systems have been shipped around
the world and the technology has generated data for more than 8,500
peer-reviewed scientific publications. The complete system includes
flexible instrumentation, proven GeneChip microarrays, optimized assays
and reagents, as well as open software architecture.
For more information on recent discoveries using Affymetrix
whole-transcript gene expression products, please visit:
Researchers Discover Expression Profiles with Distinct Splice Variants
that Improves Glial Tumor Classification
http://www.microarraybulletin.com/community/article.php?p=226
Researchers Investigate Variation in Alternative Splicing in a Human
Population
http://microarraybulletin.com/community/article.php?p=257
Gene Expression Analysis on Exon Arrays Provides High-sensitivity Results
http://www.microarraybulletin.com/community/article.php?p=258
Gene Expression Summaries and Detection of Alternative Splicing
http://www.microarraybulletin.com/community/article.php?p=256
For more information on the Affymetrix Human Gene 1.0 ST Array, please
visit: http://www.affymetrix.com/genechip/genearray.affx.
About Affymetrix
Affymetrix GeneChip® microarray
technology is the industry-standard tool for analyzing complex genetic
information. After inventing microarray technology in the late 1980s,
Affymetrix scientists have been dedicated to developing innovative
products that provide researchers with a more complete view of the
genome. These products continue to accelerate genetic research and
enable scientists to develop diagnostics and tailor treatments for
individual patients by identifying and measuring the genetic information
associated with complex diseases.
Today, Affymetrix technology is used by the world’s
top pharmaceutical, diagnostic and biotechnology companies, as well as
leading academic, government and not-for-profit research institutes.
More than 1,500 systems have been shipped around the world and more than
8,500 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Sacramento, Calif., and Singapore. The
company has about 1,100 employees worldwide and maintains sales and
distribution operations across Europe and Asia. For more information
about Affymetrix, please visit the company’s
website at www.affymetrix.com.
Forward-looking Statements
All statements in this press release that are not historical are “forward-looking
statements” within the meaning of Section 21E
of the Securities Exchange Act as amended, including statements
regarding Affymetrix’ “expectations,”
“beliefs,” “hopes,”
“intentions,” “strategies”
or the like. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially for Affymetrix from
those projected, including, but not limited to: risks and uncertainties
associated with the success of the Affymetrix Human Gene 1.0 ST Array
discussed in this press release; risks of the company’s
ability to achieve and sustain higher levels of revenue, higher gross
margins and reduced operating expenses; uncertainties relating to
technological approaches, manufacturing and product development;
personnel retention; uncertainties related to cost and pricing of
Affymetrix products; dependence on collaborative partners; uncertainties
relating to sole-source suppliers; uncertainties relating to FDA and
other regulatory approvals; competition; risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in Affymetrix’
Form 10-K for the year ended December 31, 2006, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent quarterly
periods. Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix’
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip®
are registered trademarks owned or used by Affymetrix Inc.